Study Evaluated Standardized, Novel, Enriched Biologic for Ocular Graft-vs.-Host Disease ATLANTA, GA – March 5, 2020 – Cambium Medical Technologies, a clinical stage company developing novel processed platelets for therapeutic applications, today announced receipt of results from a Phase I/II study of its Elate Ocular® topical fibrinogen-depleted human platelet lysate.  The  biologic was tested among ...